Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2023-04-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰-募集资金年度存放与使用情况鉴证报告
Regulatory Filings
2023-04-26 Chinese
百奥泰第二届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of 百奥泰生物制药股份有限公司 (Bio-Thera Solutions) held on April 26, 2023. It includes approvals of the 2022 Annual Report, 2023 Q1 Report, various board and management reports, audit committee reports, internal control evaluation, financial statements, profit distribution plans, remuneration schemes, fundraising usage reports, and other governance matters. The document repeatedly states that the actual reports are published separately on the Shanghai Stock Exchange website and media on April 27, 2023, and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself is not the full annual or quarterly report but a board meeting resolution announcement regarding these reports and other governance matters. This fits the definition of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document is over 6000 characters, so it is not a brief report publication announcement. Therefore, the correct classification is MANG with high confidence.
2023-04-26 Chinese
百奥泰 第二届监事会第六次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the sixth meeting of the second Supervisory Board of 百奥泰生物制药股份有限公司. It includes multiple agenda items such as approval of the 2022 Annual Report, 2023 Q1 Report, internal control evaluation report, financial statements, profit distribution plan, remuneration plan, fundraising usage reports, and appointment of the accounting firm. The document repeatedly states that the detailed reports are published separately on the Shanghai Stock Exchange website and media on April 27, 2023, and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full financial reports or substantive financial data but is a formal announcement of the Supervisory Board's review and approval of these reports and plans. This fits the category of Regulatory Filings (RNS) as it is a regulatory announcement of supervisory board resolutions and references other reports rather than containing the reports themselves. The document length (5358 characters) and content confirm it is not the full annual or quarterly report but a meeting resolution announcement.
2023-04-26 Chinese
百奥泰 关于部分募投项目子项目变更及金额调整的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 百奥泰生物制药股份有限公司 regarding changes and adjustments to sub-projects and amounts within their previously raised funds investment projects. It details the reallocation of funds among clinical trial sub-projects under the "drug development project" without changing the total amount of raised funds. The document includes information about the original fundraising, approvals from regulatory bodies (Shanghai Stock Exchange, China Securities Regulatory Commission), and opinions from the board, independent directors, supervisors, and the sponsoring institution. It is a formal disclosure about the use and adjustment of capital raised from an IPO, focusing on fundraising project changes and capital usage efficiency. There are no financial statements or comprehensive financial performance data presented, nor is it a full annual or interim report. It is not a call transcript, earnings release, or merger announcement. The document is a capital/financing update related to the use of raised funds and adjustments in investment projects. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7979 characters) and detailed content support this classification with high confidence.
2023-04-26 Chinese
百奥泰2022年审计报告
Regulatory Filings
2023-04-26 Chinese
中国国际金融股份有限公司关于2023年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a sponsoring institution (China International Capital Corporation) regarding the expected related party transactions for the year 2023 of Bai'ao Tai Biopharmaceutical Co., Ltd. It includes details on the nature, amounts, and approval procedures of these related party transactions. The document is a formal verification or audit opinion on these transactions rather than a full annual report, earnings release, or management discussion. It does not contain comprehensive financial statements or detailed financial analysis but focuses on compliance and procedural correctness of related party transactions. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific matters, excluding full annual reports. The document length is 3621 characters, which is consistent with a standalone audit or verification report rather than a full report or announcement. Therefore, the appropriate classification is AR with high confidence.
2023-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.